about
ARID1A mutations in endometriosis-associated ovarian carcinomasThe clonal and mutational evolution spectrum of primary triple-negative breast cancersTITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data.Genetic interrogation of circulating multiple myeloma cells at single-cell resolution.deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data.JointSNVMix: a probabilistic model for accurate detection of somatic mutations in normal/tumour paired next-generation sequencing data.PyClone: statistical inference of clonal population structure in cancer.Systematic analysis of somatic mutations impacting gene expression in 12 tumour types.Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancerDynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis.The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma.An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup.SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors.Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting.Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes.ReMixT: clone-specific genomic structure estimation in cancer.Correction to: ReMixT: clone-specific genomic structure estimation in cancer.Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors.Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.Patient-derived xenografts undergo mouse-specific tumor evolution.Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor.The Integrated Genomic Landscape of Thymic Epithelial Tumors.Using next-generation sequencing for the diagnosis of rare disorders: a family with retinitis pigmentosa and skeletal abnormalities.Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.Genomic and Functional Approaches to Understanding Cancer Aneuploidy.Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer.Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma.Genetic and transcriptional evolution alters cancer cell line drug responseTumor fraction in cell-free DNA as a biomarker in prostate cancerDetection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive DiseaseGenomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencingStructural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome SequencingDetection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid TumorsDetection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology GroupGenomic and immune profiling of pre-invasive lung adenocarcinomaGenomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsyCorrection: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology GroupGenome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring
P50
Q24610484-8BE9496B-D0FF-4BF8-BB9A-CBD011F4E83DQ29619914-FACD9348-6ABC-4A59-9D86-87ED9B044F4EQ30838548-1706232E-6EE2-46DC-9F83-0598CAD1FF96Q33664484-919ED74D-20E8-4325-9F41-1325A785D4BBQ33916606-2D19D3BF-4550-4A25-9ECE-25C19A5FC8DBQ34143680-0D0345DA-67CA-4E62-9164-C348D34272F9Q34410309-325A4559-CBAC-4786-9D00-C17341A2AAB7Q36145927-12178D58-6DC2-45D7-9542-721730FC112DQ36285430-1E6443B5-8706-4B6E-8F2D-9DACD3028BE8Q36892577-80F6B44A-1899-497B-97BF-42BA358D758DQ37063341-DCDA90AF-DED3-45DE-9793-AF38ED0D9987Q38852406-F8D08796-CBE3-4E4F-AC9D-669E287627E4Q38940501-F772C5AF-7A63-4BD9-802F-F0B5FDC9F78EQ39426445-1090D1C5-3E7C-4F84-B416-3C3D3089C8A3Q39711118-28020CED-4365-4B06-8FA1-66B54C197026Q40230451-F131E793-F9E4-43C0-A2B4-47346FAF3AE7Q41147208-ED17391D-C245-435A-87B6-47218C391043Q42371217-36714E27-235A-45F7-9D9A-FFECBF63243FQ43045850-8DA6609A-49EA-468E-9F24-E94E1F6CD196Q46129222-ED6D289F-49CC-4DEE-B1A9-2AC5D850DC7CQ46291099-9DED0B33-AD95-4C2B-BCA4-9E4D4C769959Q47214510-9658FF66-E6FB-44E9-80D5-D56B7E6BB8AEQ47723106-A2CD1047-39A3-4047-AD71-B2CB24147967Q50040409-0D6C1A43-930C-4CF8-B2C3-8E0BC6443784Q50515711-3D3C945B-AD2D-4A14-847C-76A621DE1DF9Q50983732-A42A15B9-3405-4F86-8A8C-A52A6EAF8982Q52603965-209BB4BB-10C5-423E-94EC-09C9F26CF0ECQ53100300-D42C6230-928F-4B1A-9202-A1D2FA5E0CDDQ55312090-C52769DF-334C-42BE-B29C-B7B964061991Q56550183-D42B6437-429F-4A81-A4A8-D23F12711304Q58617288-6F7C6222-2A7E-4EC6-9666-4EE0979DA87FQ64255946-161C9F60-3467-4D9B-8903-B24955BAE818Q88636696-228978C2-1144-4860-A0EF-B311EF7DD075Q89128842-A7ADCFB1-FED9-478D-8D2A-BAA3662986B5Q90354804-C958433B-1BFF-46FD-83BF-06D758342936Q91069398-EACFDE81-CF26-4230-AAF3-FF72F83BEE01Q91558572-B58472A0-1D23-4945-8964-28D339880343Q92399556-6478F7CB-E34E-4195-9A72-5A8A7D9FEB9FQ92422528-429388B7-E232-4815-BA3E-638FB66A4140Q96127680-8FCEFFCF-ADD7-4EBD-9E35-7CD05A8F5A50
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gavin Ha
@ast
Gavin Ha
@en
Gavin Ha
@es
Gavin Ha
@nl
Gavin Ha
@sl
type
label
Gavin Ha
@ast
Gavin Ha
@en
Gavin Ha
@es
Gavin Ha
@nl
Gavin Ha
@sl
prefLabel
Gavin Ha
@ast
Gavin Ha
@en
Gavin Ha
@es
Gavin Ha
@nl
Gavin Ha
@sl
P106
P21
P31
P496
0000-0001-7578-7272